1. IFNβ therapy progressively normalizes the increased ex vivo T lymphocyte apoptosis observed in active patients with multiple sclerosis
- Author
-
Antonio, García-Merino, Hugo, Barcenilla, David, Díaz, Jorge, Monserrat, Alfredo, Prieto, Melchor, Alvarez-Mon, and Ma Cruz Gutierrez del, Olmo
- Subjects
Adult ,Male ,Programmed cell death ,Multiple Sclerosis ,Time Factors ,CD3 Complex ,CD8 Antigens ,T-Lymphocytes ,medicine.medical_treatment ,Lymphocyte ,Immunology ,Apoptosis ,CD5 Antigens ,Peripheral blood mononuclear cell ,medicine ,Humans ,Immunologic Factors ,Immunology and Allergy ,Single-Blind Method ,business.industry ,Multiple sclerosis ,Interferon-beta ,T lymphocyte ,Middle Aged ,Flow Cytometry ,medicine.disease ,Treatment Outcome ,Cytokine ,medicine.anatomical_structure ,Leukocyte Common Antigens ,Female ,business ,Ex vivo - Abstract
Abnormal apoptosis has been reported in circulating T lymphocytes in patients with multiple sclerosis. The effects of 12 months of IFNbeta treatment in T and B lymphocyte spontaneous ex vivo apoptosis were studied in patients with MS. Peripheral blood mononuclear cells were obtained from 48 patients before and at 1, 6 and 12 months after treatment with IFNbeta. Spontaneous ex vivo apoptosis was quantified by four-color flow cytometry. A significant reduction and normalization of the percentage of apoptotic cells was found in all T lymphocyte subsets. B cell apoptosis values were unaffected by therapy; Relapses of the clinical activity of the disease were associated to transitory upturns of lymphocyte apoptosis. In conclusion, IFNbeta therapy progressively normalizes the increased ex vivo T lymphocyte apoptosis observed in MS. However, it is not clear if this reduction in spontaneous T lymphocyte apoptosis is due to direct effect of IFNbeta or secondary to decreased clinical and sub-clinical activity.
- Published
- 2009
- Full Text
- View/download PDF